SCHEDULE: Logos Global Management Discloses 4.1% Stake in Crescent Biopharma
Beneficial Ownership Disclosure
Logos Global Management LP and related entities have filed an amended Schedule 13G, disclosing a 4.1% passive beneficial ownership stake in Crescent Biopharma, Inc. as of June 30, 2025.
Summary
- Logos Global Management LP, along with its general partner Logos Global Management GP LLC, and Arsani William, reported beneficial ownership of 575,000 Ordinary Shares of Crescent Biopharma, Inc.
- This represents a 4.1% stake in the company, calculated based on 13,829,562 Ordinary Shares outstanding as of July 25, 2025, as reported in the Issuer's Form 10-Q.
- Logos Global Master Fund LP and its general partner Logos GP LLC reported beneficial ownership of 100,000 Ordinary Shares, representing 0.7% of the class.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to previously reported passive ownership.
- The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Crescent Biopharma, Inc.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of passive beneficial ownership, providing factual information without indicating positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Minimal direct impact on stakeholders as this is a passive ownership disclosure, not indicating any change in company operations or strategy.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires the filing of this statement, indicating the ownership threshold was met or changed. |
| 07/25/2025 | Date as of which the total outstanding Ordinary Shares (13,829,562) of Crescent Biopharma, Inc. were reported in its Form 10-Q. |
| 08/14/2025 | Date the Schedule 13G filing was signed by the reporting persons. |
Keywords
Crescent Biopharma, Logos Global Management, Schedule 13G, Beneficial Ownership, Ordinary Shares, Investment Management, Biopharma
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.